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Joseph Pidala,1,2 Claudio Anasetti,1,2 Mohamed A. Kharfan-Dabaja,1,2 Corey Cutler,3
Andy Sheldon,4 Benjamin Djulbegovic1,2Peripheral blood stem cells (PBSCs) and bone marrow (BM) hematopoietic stem cells represent therapeutic
alternatives in allogeneic hematopoietic cell transplantation. Randomized controlled trials and an individual
patient data meta-analysis (IPDMA) have demonstrated a decreased risk of disease relapse and an increased
risk of acute and chronic graft-versus-host disease (aGVHD, cGVHD) in patients receiving PBSCs compared
with those receiving BM stem cells. Decision modeling provides quantitative integration of the risks and ben-
efits associated with these alternative treatments, incorporates survival discounts for lower quality of life in
patients with aGVHD or cGVHD and post-transplantation relapse, and allows sensitivity analyses for all
model assumptions. We have constructed an externally validated Markov model to represent and analyze
the decision to use PBSC or BM, estimating post-transplantation state transition probabilities (eg, GVHD
and relapse) and quality-of-life discounts from the IPDMA and relevant literature; importantly, this IPDMA
synthesized data from primarily adult patients treated with myeloablative (MA) conditioning regimens
with T cell–replete matched sibling donors. In this setting, the model demonstrates the superiority of
PBSC over BM in both overall and quality-adjusted life expectancy, with a 7-month advantage for PBSC. Sen-
sitivity analyses support this conclusion through a range of values for each variable supported by the IPDMA
and quality-of-life discounts, as supported by the literature. However, BM is the optimal strategy in condi-
tions in which the 1-year relapse probability is\ 5%. PBSC is the optimal stem cell source in terms of
both overall and quality-adjusted life expectancy, except in conditions with a very low relapse probability,
in which BM provides optimal outcomes.
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Historically, hematopoietic stem cells for autolo-
gous and allogeneic transplantation to treat hemato-
logic malignancies have been obtained by bone
marrow (BM) harvest. however, these stem cells are in-1Departments of Blood and Marrow Transplantation,
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6/j.bbmt.2009.07.009creasingly obtained through mobilization and collec-
tion from the peripheral blood (PB) [1-5]. A review
of current trends indicates that most allogeneic stem
cell transplantations are performed using PB stem cells
(PBSCs) [6]. There are important differences in the
composition of these stem cell products, most notably
in terms of absolute CD341 cell count and donor T
cell content [7-17]. Accordingly, there is great interest
in investigating the effect of the hematopoietic stem
cell source on important outcomes in transplantation.
Numerous randomized controlled trials have com-
pared BM-harvested hematopoietic stem cells and
PBSCs and reached disparate conclusions [18-28].
A group of investigators known as the Stem Cell
Trialists set out to examine and synthesize the totality
of evidence in an individual patient data meta-analysis
(IPDMA). In total, they examined data on 1,111 pa-
tients from 9 randomized controlled trials that met
the inclusion criteria for this analysis. In primarily
adult patients treated with myeloablative (MA)1415
Table 1. Probability Estimates with Data Sources
Probability Data Source
Estimate
(PBSCT)
Adjusted for
Month Cycle
Length (PBSCT) Estimate (BMT)
Adjusted for
Month Cycle
Length (BMT)
Range for
Sensitivity
Analyses
Engraftment failure Meta-analysis 0.03 0.03 0.05 0.05 0.01-0.08
aGVHD Meta-analysis 0.412 0.137 0.379 0.126 0.12-0.8
Death from aGVHD Meta-analysis RRI*earlyTRM RRI*earlyTRM RRI*earlyTRM RRI*earlyTRM RRI: 1-5
Relapse, year 1 Meta-analysis 0.153 0.01275 0.156 0.013 0-0.3
Relapse, year 2 Meta-analysis 0.06 0.005 0.069 0.0058 0.03-0.12
Relapse, year 3 Meta-analysis 0.0143 0.0012 0.053 0.0044 0.005-0.08
Treatment success aGVHD Literature 0.4 0.067 0.4 0.067 0.25-0.75
cGVHD through year 1 Meta-analysis 0.59 0.098 0.45 0.075 0.05-0.7
cGVHD beyond Meta-analysis 0.09 0.0075 0.08 0.0067 0.05-0.15
cGVHD complications
through year 1
Meta-analysis 0.4 0.067 0.25 0.042 0.1-0.5
cGVHD complications
beyond
Meta-analysis 0.05 0.0042 0.04 0.0033 0.03-0.06
Transplant complications Literature 0.125 0.01 0.125 0.01 0.05-0.2
Treatment success cGVHD Literature 0.3 0.0083 0.3 0.0083 0-0.7
Taper IST Stewart et al. [32] 0.20 0.0056 0.4 0.011 0.05-0.5
Death from relapse, early Meta-analysis 0.07 0.0058 0.1 0.0083 0.05-0.3
Death from relapse, late Meta-analysis 0.045 0.00375 0.065 0.0054 0.04-0.08
Early TRM Meta-analysis 0.125 0.01 0.125 0.01 0.05-0.2
Late TRM Meta-analysis 0.02 0.0017 0.02 0.0017 0-0.1
Quality of life Literature estimates (see Methods)* *estimates (see methods) 0-1.0
aGVHD complications Meta-analysis 0.26 0.087 0.20 0.067 0.09-0.39
Death from cGVHD Meta-analysis RRI*lateTRM RRI*lateTRM RRI*lateTRM RRI*lateTRM RRI: 1-5
Age, years Base case 35 35 18-65
ASR mortality Literature *U.S. standard ASR mortality *U.S. standard ASR mortality
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; TRM, treatment-related mortality; IST, immunosuppres-
sive therapy; RRI, relative risk increase; ASR, age/sex/race.
1416 Biol Blood Marrow Transplant 15:1415-1421, 2009J. Pidala et al.conditioning regimens and T cell–replete matched
sibling allografts, transplantation with PBSCs led to
faster neutrophil and platelet engraftment, a significant
increase in the development of grade III/IV acute
graft-versus-host disease (aGVHD) as well as extensive
and overall chronic GVHD (cGVHD), and decreased
relapse in both late-stage and early-stage disease com-
pared with BM.Non-relapse mortality (NRM) did not
differ between the 2 groups. Overall survival (OS) and
disease-free survival (DFS) were significantly better in
the PBSC transplantation (PBSCT) group in patients
with high-risk disease [29].
Decision analysis is concerned with analyzing and
representing outcome data to recommend a course of
action that provides the optimal outcome, such as
optimal overall life expectancy or quality-adjusted
life expectancy (QALE). Although physicians intui-
tively evaluate outcome data and make decisions, deci-
sion analysis allows for an explicit, quantitative
integration of all data on the risks and benefits associ-
ated with competing treatment alternatives. A decision
model consists of health states, such as perfect health,
illness, and death. The state transition probabilities
represent the likelihood of proceeding from one state
to the next in the model. Finally, health state utilities
are the value assigned to each state, ranging from
0 to 1, with 0 representing death and 1 representing
perfect health. We used the Markov state transition
model, because the decision of BM transplantation
(BMT) versus PBSCT involves risk over time, andmultiple complicating events can occur. We have de-
signed a Markov state transition model to represent
the decision of BMT versus PBSCT, estimating state
transition probabilities and assigning expected utilities
based on the foregoing meta-analysis and, where indi-
cated, examination of the pertinent literature [30,31].
This decision analysis offers novel information regard-
ing the impact of stem cell source on transplantation
outcome by quantitatively integrating the competing
risks and benefits of PBSC and BM to recommend
a strategy for optimal outcome. In addition, incorpora-
tion of health state utilities allows a comparison of
QALE among these alternatives. Finally, sensitivity
analyses examine a range of potential values for each
variable in the model, such as relapse or cGVHD, pro-
viding insight into the conditions under which these
conclusions hold true.METHODS ANDANALYSIS
We constructed a Markov decision model to repre-
sent the decision of PBSCTversus BMTusingTreeAge
Pro 2008 software (see Supplementary Appendix A).
Following a decision node of PBSCT versus BMT,
cloned Markov trees follow with a structure consisting
of the following distinct health states important to he-
matopoietic stem cell transplantation: transplantation,
engraftment failure, aGVHD, cGVHD, relapse, on im-
munosuppressive therapy (IST), off IST, death from
Biol Blood Marrow Transplant 15:1415-1421, 2009 1417Decision Analysis of PBSCT versus BMTrelapse, and death. Transition probabilities were esti-
mated primarily from the Stem Cell Trialists individual
patient data meta-analysis (IPDMA), and, where indi-
cated, estimates were gathered from a search of relevant
literature (seeTable 1 for probability estimates). Impor-
tantly, probability estimateswere adjusted to conform to
a 1-month cycle length in the model. Health state utili-
ties were estimated for calculatingQALE in the quality-
adjusted model. Analyses were performed using cohort
analysis; this analysis includes the entire time horizon,
extrapolating beyond the available data. Future dis-
counting was not included. Modeling assumptions
were tested extensively, and the model was validated ex-
ternally through comparison of major outcomes pre-
dicted with those reported in the meta-analysis (see.
Appendix B). In addition, sensitivity analyses were per-
formed on all transition probability estimates and health
state utilities to examine the impact of a range of values
for each on the reported outcome.
Base Case Assumptions
A base case age of 35 years was assumed in this
analysis, in keeping with the age distribution of the tri-
als represented in the IPDMA. Sensitivity analyses
examined an age range of 18 to 65 years.
State Transition Probabilities
Here, engraftment is defined as sustained neutro-
phil engraftment (sustained absolute neutrophil count
of 0.5 109/L), with the probability estimate obtained
from the IPDMA. Engraftment failure is defined as
(1-probability of engraftment). The probability of
aGVHD is defined as the probability of grade II-IV
aGHVD from 100-day cumulative incidence reported
in the IPDMA. The probability of aGVHD complica-
tions represents the probability of grade III/IV
aGHVD as reported in the IPDMA. The probability
of cGVHD is estimated from that of ‘‘any-stage
cGVHD’’ in the IPDMA; the probability of cGVHD
complications is used as a distinct probability to
approximate ‘‘extensive-stage cGVHD’’ from the
IPDMA. The probability of cGVHD for PBSCT
and BMT is classified as that occurring ‘‘early’’ (within
1 year) or ‘‘late’’ (beyond 1 year). The probability of
treatment success for aGVHD is defined as complete
resolution of aGVHD after treatment with corticoste-
roids, with the probability estimated at 0.4 from the lit-
erature. Treatment success for cGVHD is defined as
complete resolution of cGVHD with therapy, with
an estimate of 0.3 obtained from a literature review.
The probability of tapering IST is modeled after Stew-
art et al. [32], where probability of tapering off IST at 3
years was 0.4 for BMT and 0.2 for PBSCT. The prob-
ability of treatment-related mortality (TRM) is de-
fined as follows. Nonrelapse mortality (NRM) from
the IPDMA is assumed to be comprised of mortalityfrom GVHD (aGVHD and cGVHD) and also non–
GVHD-related TRM. This NRM is classified into
that occurring before and that occurring after 12
months post-transplantation. Half of the NRM
through this time point is assumed to result from
TRM, or early TRM. aGVHD mortality is then
expressed as the product of TRM * relative risk in-
crease (RRI). Half of the NRM occurring beyond 12
months posttransplantation is assumed to result from
late TRM, with cGVHD mortality expressed as late
TRM * RRI. A range of values for this RRI have
been examined, given the uncertainty regarding rela-
tive contribution to NRM from GVHD and non–
GVHD-related TRM. The probability of relapse is
modeled after the cumulative incidence of relapse in
the IPDMA for PBSCT and BMT; specifically, it is
based on the overall relapse probability, whereas the
range of relapse probabilities encompassed by early-
stage and late-stage disease is examined in sensitivity
analyses. In the IPDMA, early-stage disease included
chronic myelogenous leukemia (CML) in first chronic
phase, acute myelogenous leukemia (AML), and acute
lymphoblastic leukemia (ALL) in first compete remis-
sion (CR1), and refractory anemia (RA)/refractory
anemia with excess blasts (RAEB)myelodysplastic syn-
dromes (MDS); conversely, late-stage disease included
CML in second chronic phase, accelerated phase or
blast crisis, AML or ALL either refractory or in CR2
or beyond, RAEB or in transformation subtypes of
MDS, multiple myeloma (MM), Hodgkin disease
(HD), non-Hodgkin lymphoma (NHL), and idio-
pathic myelofibrosis. To model the risk for relapse in
accordance with the varying slope in the relapse curve,
the probability of relapse in this model is further
divided into early relapse, occurring up to 1 year
post-transplantation, and late relapse, described for
year 2 and then year 3 and beyond. The probability
of relapse mortality is modeled after the relapse-re-
lated mortality curve in the IPDMA; relapse mortality
estimates are divided into early (occurring within 1
year) and late (occurring after 1 year), to recapitulate
that seen in the relapse mortality curve. For baseline
age/sex/race (ASR)-based mortality, the standard
ASR-based mortality table for the U.S. population
from relevant literature is used; these are adjusted to
adhere to the month cycle length in this model.Health State Utilities
In this model, health state utilities represent the
quality of life associated with each state. These health
state utilities are incorporated into the quality-
adjusted model to estimate QALE. Our assumptions
in this model were as follows: The starting state of
transplantation was assigned a utility of 1.0, which rep-
resents the starting state of optimal health. Although
we have found no literature to support the assignment
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Figure 1. Overall survival.
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1418 Biol Blood Marrow Transplant 15:1415-1421, 2009J. Pidala et al.of a state utility for engraftment failure, here we as-
sumed that this would be no better than the relapse
state, and assigned it a value of 0.57.We assigned a util-
ity of 0.78 for aGVHD; although there is no direct re-
port of aGVHD state utility in the literature, we
modeled this after the utility reported by Sullivan
et al. [33], who derived utilities for a wide range of
health states from EQ-5D scores in a large U.S. popu-
lation survey. We estimated that aGVHD would most
closely approximate the conditions ‘‘hepatitis’’ and/or
‘‘non-infectious gastroenteritis.’’ We assigned a utility
of 0.9 to cGVHD, based on that reported by Lee et al.
[34] as derived by standard gamble methods. We as-
signed a utility of 0.57 to relapse based on that derived
by standard gamble methods and reported by Cutler
et al. [35] and Sung et al. [36]. We assigned a utility
of 0.979 to on IST, which is assumed to approximate
that reported for ‘‘mean utility for life without chronic
graft-versus-host disease after transplantation’’ by Lee
et al. [34]. We assigned a utility of 0.99 to off IST, as-
suming that the utility for this state lies between that of
on IST and the starting state of transplantation. We
tested these assumptions in sensitivity analyses.
Model Validation
The model structure, definitions, and assumptions
were tested extensively. As an external validation, we
compared our predicted outcomes with those reported
in the IPDMA (see Appendix B). We compared the re-
sults generated by this model with the cumulative inci-
dence data from the IPDMA. The outcomes predicted
by this model closely approximate those from the
IPDMA. Specifically, there is strong concordance be-
tween the model and the IPDMA for OS, DFS,
cGVHD, relapse, and NRM. The relapse mortality
generated by the model exceeds that seen in the
IPDMA. In addition, aGVHD is lower in the model,
reflecting a model structure that favors transition
away from the aGVHD state to cGVHD, on IST,
and death. Importantly, however, the model consis-
tently produces outcomes that are qualitatively con-
cordant with the IPDMA data.51
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Using the methods described we constructed
a Markov model and populated it with probability es-
timates and state utilities. In the unadjusted model, as-Table 2. Survival Outcomes for PBSCT versus BMT
PBSCT BMT
Overall life expectancy, months 61 54
QALE 56 49
PBSCT indicates peripheral blood stem cell transplantation; BMT, blood
marrow transplantation; QALE, quality-adjusted life expectancy.suming a base case age of 35 years, the overall
predicted life expectancy was 61 months for PBSCT
and 54 months for BMT (Table 2). This projected
life expectancy reflects the area under the survival
curve. In addition, 5-year OS was 55% for PBSCT
and 46% for BMT (Figure 1). The survival curves
produced by the model closely approximate those
reported in the meta-analysis.
We performed sensitivity analyses to challenge the
assumed transition probabilities and health state
utilities in this model across a range of potential values.
We first performed one-way sensitivity analyses for
all transition probabilities in the unadjusted model.
These consistently demonstrated intuitive relation-
ships in which an increasing probability of an adverse
variable over a range of values leads to a decreased
overall life expectancy.
In all other variables examined except probability
of post-transplantation relapse, PBSCT was superior
to BMT throughout the entire range of anticipated
values. However, there was a strong negative relation-
ship between the probability of relapse and expected
overall survival. In one-way sensitivity analyses exam-
ining the probability of relapse in BMT, PBSCT was
superior in a range inclusive of the values reported45
47
49
0 0.05 0.1 0.2 0.30.15 0.25
1 year relapse probability
Figure 2. One-way sensitivity analysis examining early relapse risk in
BMT in the unadjusted model (baseline value, 0.156).
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Figure 3. One-way sensitivity analysis examining the cGVHD state util-
ity (baseline value, 0.9).
Biol Blood Marrow Transplant 15:1415-1421, 2009 1419Decision Analysis of PBSCT versus BMTfor early-stage and late-stage disease in the IPDMA;
only at a relapse probability below that reported in
the IPDMA (here 1-year relapse probability\ 0.05)
did BMT become the optimal strategy (Figure 2).
Because the IPDMA reported a greater risk of
cGVHD in PBSCT and a greater risk for relapse in
BMT, we examined these as competing risks in two-
way sensitivity analyses. In the comparisons of the prob-
ability of cGVHD in PBSCT versus the probability of
early and late relapse in BMT in the unadjusted model,
PBSCT retained its superiority, except at very low re-
lapse probability (1-year relapse probability\ .05).
We re-examined these relationships in the quality-
adjusted model. Here again, PBSCT retained its supe-
riority, with a QALE of 56 months for PBSCT and 49
months for BMT (Table 2). One-way sensitivity anal-
yses again produced logical relationships and demon-
strated the superiority of PBSCT over BMT, with
the exception of extremes of relapse probabilities lying
outside those values reported in the IPDMA. One-way
sensitivity analyses of early and late relapse in the BMT
arm consistently showed that PBSCTwas superior, ex-
cept at very low relapse probability (1-year relapse
probability\ .06). Two-way sensitivity analyses com-
paring the probability of cGVHD in PBSCT versus
that of relapse in BMT demonstrated that PBSCT re-
tained its superiority, except at a 1-year relapse proba-
bility\ .05. Disease conditions with this low relapse
probability include aplastic anemia (AA), refractory
anemia (RA), and congenital marrow failure syn-
dromes [37-41].
We also performed sensitivity analyses for each of
the health state utilities to examine the impact of a po-
tential range of values for each on the outcome. Given
the relative uncertainty regarding these state utilities,
we examined a broad range (0-1.0) for each. For all
utilities except cGVHD, PBSCT had the optimal ex-
pected values throughout this range. For cGVHD,
a trade-off was realized at a utility of 0.18; BMT be-
came the optimal strategy at values below this point
(Figure 3). As a frame of reference, the health state util-
ity is 0 for death, 0.57 for relapse, 0.9 for cGVHD, and
1 for perfect health [33-36].DISCUSSION
Decision analysis is a powerful tool that allows the
quantitative integration of all data on the risks and
benefits associated with competing treatment alterna-
tives. This approach has been used to address impor-
tant clinical questions in allogeneic hematopoietic
cell transplantation, including optimal strategies for
unrelated donor transplantation in CML [34] and the
optimal timing of allogeneic transplantation in specific
MDS risk categories [35]. The results of these models
have strongly influenced clinical practice. Here, wehave designed a decision model to discern the impact
of hematopoietic stem cell source on outcomes, and
also to investigate the competing threats of cGVHD
and relapse on overall life expectancy and QALE.
Our Markov model strongly supports PBSCT as the
optimal strategy in terms of both overall life expec-
tancy and QALE, with an advantage of 7 months for
PBSCT over BMT. In addition, one-way sensitivity
analyses for all major variables support this conclusion,
with PBSCT remaining the optimal strategy through-
out the range of values supported by the IPDMA. Be-
cause the evidence to date appears to indicate that
cGVHD in PBSCT and disease relapse in BMT ap-
pear to be competing risks, we examined these in
two-way sensitivity analyses. In all of the analyses re-
ported here, relapse emerges as a significant threat to
overall life expectancy andQALE.This is clear in anal-
yses examining the probability of relapse in BMT, in
which PBSCT was superior up to very low relapse
probabilities, which are not seen in the IPDMA. We
also made the opposite comparisons, namely, one-
way sensitivity analyses for relapse in PBSCT, as well
as two-way sensitivity analyses comparing relapse in
PBSCT versus cGVHD in BMT. These comparisons
demonstrate that at relapse probabilities far exceeding
those reported for PBSCT in the IPDMA (1-year re-
lapse probability . 0.28), a trade-off point is reached
leading to BMT as the optimal strategy.
Taken together, our results demonstrate the ad-
verse impact of disease relapse and suggest that the
superiority of PBSCT in this model is driven largely
by the discrepant relapse probabilities in PBSCT and
BMT. They also support the finding that, despite the
greater extent of cGVHD seen in PBSCT, overall
life expectancy and QALE are superior in PBSCT,
which is consistent with the greater mortality and
worse quality of life seen in relapse compared with
cGVHD. This has important implications for clinical
practice, as most hematopoietic cell transplantations
(HCTs) now use PBSCs rather than BM-harvested
stem cells.
1420 Biol Blood Marrow Transplant 15:1415-1421, 2009J. Pidala et al.Our conclusions regarding the superiority of
PBSCT over BMT in terms of QALE are especially
robust in light of the consistency of this finding across
a very broad range of potential values for each health
state utility. Only at a utility\ 0.18 for cGVHD did
the optimal path change from PBSCT to BMT. This
value is a marked decrement compared with the pub-
lished estimates of health state utility associated with
cGVHD, which suggest a value of 0.9 with a reference
state of perfect health of 1.0 [34]. Although the litera-
ture to support the estimate of 0.9 is singular, it is un-
likely that others would differ to this extent.
Besides supporting the superiority of PBSCT over
BMT and demonstrating that the adverse impact of
cGVHD is outweighed by the lower risk of disease re-
lapse in both overall survival and QALE, our model
has other potential applications as well. This externally
validated model could be used to answer specific ques-
tions related to transplantation outcome when applied
to specific disease or transplantation conditions. Of
note, PBSCT remained superior throughout the range
of relapse probabilities examined to encompass that
reported for early-stage and late-stage disease in the
IPDMA; thus, this conclusion would apply to the con-
ditions represented therein. However, at very low
1-year relapse probabilities (ie,\ .05), there is a transi-
tion point below which BMT becomes the optimal
strategy for overall life expectancy and QALE. There-
fore, in certain conditions with potentially very low re-
lapse risk below this threshold (eg, nonmalignant
disorders like hemoglobinopathies, RA, congenital
marrow failure syndromes, acquired AA), the model
supports BMT as the optimal strategy [37-41]. This
shift in optimal strategy likely reflects the unopposed
burden of cGVHD imposed by PBSCT in this setting.
Importantly, primary data from adults with T cell–re-
plete matched related donors informed this decision
model; accordingly, whether outcomes are superior
with PBSCT compared with BMT in unrelated donors
or in pediatric transplantation remains unknown.ACKNOWLEDGMENTS
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